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1. Was the level of first line bDMARD prescriptions what you would expect for your study population? 2. You mention the new JAKis in your introduction but this analysis does include these drugs so perhaps remove this reference? 3. The results show data on persistence based on prescriptions but you do not mention that prescription does not equal adherence and what effect this might of had on your results? 3. Although you did stratify your analysis by those who were prescribed bDMARDs before and after 31/12/2009, did you stratify year on year as those who were prescribed the bDMARDs in the very early days, were likely to be those with the most severe disease so may have biased your results? 5. Although you mention unmeasured confounders in the discussion, perhaps you could provide examples in the discussion relating to possible unmeasured confounders in this analysis?
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GENERAL COMMENTS
This study is based on analysis of a biologic registry to examine persistence of biologic agents when used first line monotherapy is well conducted. The main weakness is that the number of patients receiving non-TNF inhibitors are relatively small so do not have sufficient power to discriminate potential differences. This needs to be highlight in the discussion and abstract. Indeed, given the main comparison is between TNF inhibitors, the title should be changed to reflect that the main observation is between TNF inhibitors.
VERSION 1 -AUTHOR RESPONSE
Reviewer(s) Reports:
Reviewer: 1 This is a nicely written and well thought out paper that addresses the objectives to assess the comparative effectiveness of different bDMARDs when administered as monotherapy compared to combination therapy in patients with RA.
We thank the reviewer for this comment. Although you mention unmeasured confounders in the discussion, perhaps you could provide examples in the discussion relating to possible unmeasured confounders in this analysis?
We have expanded the sentence in "Discussion" chapter according to this suggestion (page 20) .
Reviewer: 2
This study is based on analysis of a biologic registry to examine persistence of biologic agents when used first line monotherapy is well conducted. The main weakness is that the number of patients receiving non-TNF inhibitors are relatively small so do not have sufficient power to discriminate potential differences. This needs to be highlight in the discussion and abstract. Indeed, given the main comparison is between TNF inhibitors, the title should be changed to reflect that the main observation is between TNF inhibitors. 
